Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | DRD5 | P21918 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2075262 | 0.94 | DRD2 (0.50) | DRD2KMT2AKDM4ECYP1A2CYP2D6 | |
| SCHEMBL11732086 | 0.83 | DRD2 (0.53) | DRD2KMT2AKDM4ECYP1A2CYP2D6 | |
| SCHEMBL29699237 | 0.80 | DRD2 (0.46) | DRD2DRD3HSD17B10 | |
| SCHEMBL2372239 | 0.80 | DRD2 (0.46) | DRD2DRD3HSD17B10 | |
| SCHEMBL2372244 | 0.80 | DRD2 (0.46) | DRD2DRD3HSD17B10 | |
| SCHEMBL11732168 | 0.75 | DRD2 (0.56) | DRD2KMT2AKDM4ECYP1A2CYP2D6 | |
| SCHEMBL11738258 | 0.75 | DRD2 (0.54) | DRD2KMT2AKDM4ECYP1A2CYP2D6 | |
| SCHEMBL11735439 | 0.74 | DRD2 (0.52) | DRD2KMT2AKDM4ECYP1A2CYP2D6 | |
| SCHEMBL11735877 | 0.73 | DRD2 (0.54) | DRD2KMT2AKDM4ECYP1A2CYP2D6 | |
| SCHEMBL11731551 | 0.73 | DRD2 (0.56) | DRD2KMT2AKDM4ECYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059989-A1 | 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF AIRWAY DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059989-A1 | 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF AIRWAY DISEASES | CFTR, SCN5A, SCNN1B | DRD2 688/4885KMT2A 3871/4885KDM4E 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.